Selected References:
- Auerbach JG, Hans SL, Marcus J, Maeir S. 1992. Maternal psychotropic medication and neonatal behavior. Neurotoxicol Teratol 14:399-406.
- Chan J, Alldredge BK, Baskin LS. 1991. Perphenazine-induced priapism. DICP 24:246-9
- FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/089683s024lbl.pdf
- FDA Drug Safety Communication. 2011. Antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns: http://www.fda.gov/Drugs/DrugSafety/ucm243903.htm.
- Handal M, Matheson I, Bechensteen AG, Lindemann R. 1995. [Antipsychotic agents and pregnant women. A case report]. Tidsskr Nor Laegeforen;115:2539-40.
- Harer WB: Tranquilizers in obstetrics and gynecology. 1958. Studies with Trilafon. Obstet Gynecol 11:273-9.
- Idapaan-Heikkila J, Saxen L. 1973. Possible teratogenicity of imipramine/chloropyramine. Lancet 2:282-4.
- Liu X, Trabjerg BB, Munk-Olsen T, Christensen J, Dreier JW. 2022. Association of Maternal Antipsychotic Prescription During Pregnancy With Standardized Test Scores of Schoolchildren in Denmark. JAMA internal medicine. 182(10):1035-43.
- Olesen OV, Bartels U, Poulsen JH. Perphenazine in breast milk and serum. 1990. Am J Psychiatry;147:1378–9.
- Reis M, Kallen B. 2008. Maternal use of antipsychotics in early pregnancy and delivery outcome. Journal of clinical psychopharmacology;28(3):279–88.
- Slone D et al. 1977. Antenatal exposure to the phenothiazines in relation to congenital malformations, perinatal mortality rate, birth weight, and intelligence quotient score. Am J Obstet Gynecol 128:486-8.
- Wertelecki W et al. 1980. Amitriptyline/perphenazine maternal overdose and birth defects. Teratology 21:74A.
